Improved ProfitabilityThe move from a net loss to a positive 0.9% net margin and a stronger EBITDA margin (5.6%) signals operational stabilization and better cost control. Sustained margin recovery increases internal funding capacity for R&D and commercialization, improving strategic flexibility over the next several months.

Balanced Leverage And Capital StructureA debt-to-equity near 1.0 with an equity ratio of 38.5% reflects a measured leverage profile and solid capital base. This provides resilience against cyclical shocks, reduces refinancing risk, and supports medium-term investment in the product pipeline or manufacturing capacity without immediate solvency pressure.

Predictable Domestic Pharma ModelA focus on prescription drug sales within Japan’s regulated market yields relatively stable demand and reimbursement visibility. Combined with revenue channels like licensing and contract manufacturing, the business model supports recurring cash flows and strategic options that remain relevant over a 2–6 month horizon.

Bears Say

Negative Free Cash FlowPersistent negative free cash flow and operating cash flow indicate difficulty converting accounting profits into cash. This constrains capacity to self-fund R&D, capex, or dividends and raises reliance on external financing, creating medium-term liquidity and strategic execution risks.

Inconsistent Revenue GrowthVolatile top-line performance—growth one year after decline—reduces predictability of future earnings and complicates planning for commercialization and pipeline investment. Inconsistency may reflect product concentration or pricing pressures, undermining durable revenue visibility.

Low Operating MarginsModest gross and very low EBIT margins limit the company’s ability to absorb cost increases and to generate surplus for reinvestment. Low operating profitability reduces slack to scale commercial activities or accelerate R&D, making sustained earnings improvement more challenging over the medium term.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1410.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥6.42B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 61 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jan 30, 2026. The company reported ¥34.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥34.21.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.21%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of ¥34.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.